Merck Acquires Investigational B-Cell Disease Drug For $1.3 Billion
Merck's Acquisition of CN201: A Strategic Expansion in B-Cell Disease Treatment.
Disclaimer: This article is intended for informational purposes only and should not be construed as financial or medical advice. Always consult a professional for expert opinions.
Real-time information is available daily at https://stockregion.net